samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

ROUSSELOT INTRODUCES X-PURE® GelMA FOR TRANSLATIONAL MEDICINE

Rousselot


Irving, United States [03 June 2020] — Rousselot, a Darling Ingredients brand and the global leader of collagen-based solutions, takes on the digital challenge and introduces X-Pure® GelMA at Bio Digital 2020. The first GMP-ready range of gelatin methacryloyl (GelMA) biomaterials suitable for preclinical and clinical applications, X-Pure® GelMA is part of the X-Pure portfolio of ultra-pure gelatins and collagens, suitable for use as biomaterials in 3D bioprinting, tissue engineering, and regenerative medicine.

GelMA, the most versatile biological environment for cells
Methacryloyl is a commonly used crosslinker, important to increase the melting point and mechanical strength of gelatin-based constructs. In GelMA hydrogels, the inherent bioactivity, biodegradability, and cell compatibility of gelatin are combined with the tailorability of photo-crosslinking. This combination holds a huge potential for the creation of tunable biological environments for the culture of various eukaryotic cells at body temperature.

X-Pure GelMA - The first GMP-ready gelatin methacryloyl
GelMA-oriented patent applications have been growing exponentially over the last 5 years, with many of these research concepts now being translated into the clinic. However, standard GelMA products often carry high and variable levels of soluble impurities originating from either the gelatin raw material or the chemical synthesis process. The presence of these impurities such as endotoxins and/or MA residues are detrimental for in-body use but can also affect the success of in vitro applications.

Rousselot’s unique purification process, centered around a two-stage routine, results in ultra-low levels of pyrogens and residual methacrylic acid, providing an excellent safety profile to the product. Further, consistent batch-to batch quality ensures reliable results and shorter lead times to the clinic.

Readily available, X-Pure GelMA can be produced in compliance with GMP regulatory requirements for quality, raw material sourcing, and documentation for approval across all major regulators worldwide, thereby minimizing regulatory risks and optimizing the pace of product development.

With full and validated traceability of raw materials, and with ultra-low levels of impurities such as pyrogens and methacrylic acid, X-Pure GelMA can significantly reduce time to clinic”, explains Tanja Vervust, Global Director Rousselot Biomedical. ‘Rousselot’s global presence and biomaterials expertise enable access to an extensive IP portfolio as well as a reliable security of supply, providing real added value to the high purity of the new range.’

The new range covers a broad choice of molecular weights and modification degrees of gelatin methacryloyl biomaterials. This allows close collaboration with customers to determine the right specifications to accurately produce custom-made solutions.
phone +31 499 364100
email Gelatin@rousselot.com
web www.rousselot.com
email Rousselot BV, Kanaaldijk Noord 20 5691 NM SON
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR gene

LONDON - (BUSINESS WIRE) - Apr. 28, 2021- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF)
More info >>


White Papers

e-tools enhance clinical trial performance

e-novex

In today’s ever-evolving medical business, technological changes require innovation to meet growing market demands and to bring about advances in the industry. One such development currently taking place in the field of clinical research is how e-tools are initiating a boost in the productivity of clinical trials.
More info >>

Industry Events

MedTech Integrates 2021

22 June 2021, VIRTUAL CONFERENCE

Inspired by the success of the inaugural MedTech Integrates in last October, Life Science Integrates is delighted to announce the second Medtech Integrates conference. This one-day gathering of technology, diagnostics, devices and therapeutics organisations, as well as clinicians and regulators, provides a platform to discuss the major challenges impacting the MedTech sector.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement